← Back to all trials
Completed
NCT00368537
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
Conditions: Skin Diseases, Bacterial
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 550
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Location: Scottsdale Arizona
Summary
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
Eligibility Criteria
Inclusion Criteria:
* Clinical diagnosis of complicated skin or skin structure infection
* Male or female, 18 years or older
* Need for intravenous treatment for 4 to 14 days
Exclusion Criteria:
* Skin infection that can be treated by surgery \& wound care alone
* Diabetic foot ulcers or bedsores where the infection is present longer than 1 week
* Poor circulation such that amputation of the infected site is likely within a month Other exclusions apply
Source: ClinicalTrials.gov (NCT00368537). StuddyBuddy aggregates publicly available trial information.